Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Pfizer won Lyrica patent infringement case
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Nov 3, 2012 11:09:14
Pfizer won its patent infringement case of Lyrica against ten Korean generic drugmakers, including CJ, Pfizer Korea said Wednesday.

The Korea Intellectual Property Tribunal recently sided with Pfizer Korea, ruling that the patent on Lyrica’s use for neuropathy is still valid.

The latest ruling is likely to affect the preliminary injunction filed by Pfizer Korea against generic drugmakers who have promoted their generic version as the treatment of neuropathy. The ruling about the preliminary injunction hasn’t come yet.

If Pfizer also win the case, it may file a lawsuit against CJ to restore its financial damage caused by CJ’s A-Gabalin.

Lee Dong Su, President of Pfzier Korea said, “We respect the Tribunal’s ruling which validated the patents on Lyrica. We will keep protecting out patent thoroughly.”
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com